Table 3.
Main characteristics and outcomes of the sample, stratified by gender and vaccine status.
| Variables | Overall Sample | ≥1 Vaccine Dose | Unvaccinated |
|---|---|---|---|
| SARS-CoV-2 positive swab, % (n) A | |||
| - Females (n = 127,839) | 2.76 (3527) | 0.13 (53) | 3.93 (3474) |
| - Males (n = 117,387) | 2.99 (3506) | 0.11 (32) | 3.97 (3474) |
| Covid-19 disease, % (n) A | |||
| - Females | 0.31 (401) | 0.03 (12) | 0.44 (389) |
| - Males | 0.47 (550) | 0.02 (6) | 0.62 (544) |
| Death, % (n) A | |||
| - Females | 0.09 (109) | 0.01 (2) | 0.12 (107) |
| - Males | 0.12 (135) | 0.00 (1) | 0.15 (134) |
| Cox model * | SARS-CoV-2 | COVID-19 | Death |
| HR (95% CI) | HR (95% CI) | HR (95% CI) | |
| ≥1 Vaccine dose vs. none B | |||
| - Females (n = 39,550) | 0.06 (0.04–0.08) | 0.06 (0.03–0.11) | 0.04 (0.01–0.15) |
| - Males (n = 29,989) | 0.04 (0.03–0.06) | 0.02 (0.01–0.05) | 0.02 (0.00–0.11) |
| Only one vaccine dose vs. none C | |||
| - Females (n = 20,529) | 0.16 (0.12–0.22) | 0.44 (0.24–0.79) | 0.28 (0.04–2.04) |
| - Males (n = 16,155) | 0.16 (0.11–0.23) | 0.20 (0.09–0.44) | 0.27 (0.04–1.94) |
| Two vaccine doses only vs. none D | |||
| - Females (n = 19,021) | 0.03 (0.02–0.05) | 0.01 (0.00–0.06) | 0.04 (0.01–0.27) |
| - Males (n = 13,834) | 0.01 (0.01–0.03) | 0.00 (NE) | 0.00 (NE) |
HR = Hazard Ratio; CI = Confidence Interval; NE = Not estimable (0 cases in one of the two groups). * Adjusted for age, hypertension, diabetes, major cardiovascular diseases, chronic obstructive pulmonary diseases, kidney diseases, cancer. A After 14 (BNT162b2 or mRNA-1273) or 21 (ChAdOx1 nCoV-19) days from the administration of the first dose for the vaccinated subjects, and after 16 January 2021 for the unvaccinated subjects. B Administered at least 14 (BNT162b2 or mRNA-1273) or 21 (ChAdOx1 nCoV-19) days before the end of follow-up (21 May 2021). C Those who received the second dose were excluded from the analysis; the overall sample was thus composed of 212,371 subjects. D The comparative analysis of the second dose was restricted to a total of 206,878 subjects—13,414 were excluded as they received the second dose less than 14 days before the end of the follow-up (21 May 2021); 25,364 were excluded because they only received the first dose of vaccine; 181 were excluded because they had a SARS-CoV-2-positive swab after the start of the follow-up of the first dose (14 or 21 days after the first dose, see point C, Table 1) but before the start of the follow-up of the second dose (14 days after 2nd dose administration).